<code id='8F5757B847'></code><style id='8F5757B847'></style>
    • <acronym id='8F5757B847'></acronym>
      <center id='8F5757B847'><center id='8F5757B847'><tfoot id='8F5757B847'></tfoot></center><abbr id='8F5757B847'><dir id='8F5757B847'><tfoot id='8F5757B847'></tfoot><noframes id='8F5757B847'>

    • <optgroup id='8F5757B847'><strike id='8F5757B847'><sup id='8F5757B847'></sup></strike><code id='8F5757B847'></code></optgroup>
        1. <b id='8F5757B847'><label id='8F5757B847'><select id='8F5757B847'><dt id='8F5757B847'><span id='8F5757B847'></span></dt></select></label></b><u id='8F5757B847'></u>
          <i id='8F5757B847'><strike id='8F5757B847'><tt id='8F5757B847'><pre id='8F5757B847'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:139
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Nonprofit, backed by Microsoft, to certify AI tools in health care
          Nonprofit, backed by Microsoft, to certify AI tools in health care

          AdobeAgroupofacademichospitalsandtechnologycompanieswillformanewnonprofitventuretooverseeanationwide

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

          SipaviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletter